Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) CTO Michael Skynner sold 972 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $21,636.72. Following the transaction, the chief technology officer now owns 92,945 shares in the company, valued at $2,068,955.70. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Bicycle Therapeutics Price Performance
NASDAQ BCYC opened at $23.60 on Monday. The firm has a market capitalization of $1.01 billion, a PE ratio of -5.30 and a beta of 0.89. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.77 and a quick ratio of 14.77. Bicycle Therapeutics plc has a 12 month low of $12.54 and a 12 month high of $28.20. The company’s 50 day simple moving average is $23.36 and its 200 day simple moving average is $22.90.
Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.33. Bicycle Therapeutics had a negative return on equity of 32.80% and a negative net margin of 417.88%. The company had revenue of $9.36 million for the quarter, compared to the consensus estimate of $6.13 million. The business’s quarterly revenue was down 17.9% compared to the same quarter last year. As a group, equities research analysts forecast that Bicycle Therapeutics plc will post -3.17 EPS for the current fiscal year.
Hedge Funds Weigh In On Bicycle Therapeutics
Analysts Set New Price Targets
BCYC has been the subject of several research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $48.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Needham & Company LLC restated a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Monday, September 16th. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 target price on shares of Bicycle Therapeutics in a research report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Bicycle Therapeutics in a report on Monday, September 16th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Bicycle Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $44.56.
Get Our Latest Stock Analysis on BCYC
Bicycle Therapeutics Company Profile
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Read More
- Five stocks we like better than Bicycle Therapeutics
- With Risk Tolerance, One Size Does Not Fit All
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- How to invest in marijuana stocks in 7 stepsĀ
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.